Temodar medication errors
Executive Summary
FDA and Schering-Plough are working on labeling changes for cancer therapy Temodar following seven medication error reports with two fatalities. Errors relate to two types of confusion: mix-up between product packaging's statement of quantity and dosage; and overdose. On Temodar packaging, "the strength appears directly beside the net quantity statement," FDA said. In two overdose cases, "patient was to receive temozolomide daily for five days, then be off for 23 days," but instead continued therapy for as much as three weeks. "It is unclear from the report narratives whether the error occurred due to a verbal or written miscommunication of the dosing instructions at the patient level or the pharmacy level," FDA said...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.